PubMed Health⌕ Search

Biomedical subjects

A Sjögren

Publications and source records attributed to A Sjögren.

At least 127 records · Page 7Linked to original sources
PubMedDate not supplied

Internalization of cellular fragments in a human embryo: time-lapse recordings.

An observation is reported of internalization of a cellular fragment into a blastomere from a human embryo, as documented by time-lapse photography. The fragment, created during the first mitotic cleavage was reabsorbed into one of the mother blastomeres in less than 5 min. The time-lapse sequence, shown here as a series of still photographs, provides the first direct evidence that cellular fragments in human embryos can 'disappear' during the culture period, a phenomenon that is common in human IVF. The time-lapse sequence itself may be viewed on the internet at www.rbmonline.com/Article/633.

Blastomeres↗
PubMedDate not supplied

Hemodynamic effects of ICI 118.587 (Corwin) in patients with mild cardiac failure after myocardial infarction.

The aim of this study was to compare the effects of intravenous ICI 118.587 (Corwin), a new cardioselective partial beta-agonist, and placebo given q. 12 h for 4 consecutive days, with invasive and noninvasive methods. Twelve patients with mild to moderate cardiac failure after a myocardial infarction were studied. We could not show any significant effect of Corwin on hemodynamics, systolic time intervals, heart rates, or blood pressures. We conclude that Corwin does not affect left ventricular function, as measured by hemodynamics and systolic time intervals, in the immediate postinfarction period in patients with mild to moderate heart failure.

Adrenergic beta-Agonists↗
PubMedDate not supplied

Frusemide pharmacokinetics in patients with liver disease.

Frusemide 80mg was administered intravenously to 10 patients with alcoholic liver disease (fatty liver and Laemnec's cirrhosis). Protein binding was correlated with serum albumin concentrations (r = 0.860, p < 0.001). The apparent volume of distribution ranged between 180 and 1206ml/kg body weight and correlated with the serum albumin concentration (r = 0.710, p < 0.05) and the fraction of unbound drug (r = 0.758, p < 0.05). This fraction was 1.9 +/- 0.2% in controls and 3.1 +/- 0.9% in patients with cirrhosis (p < 0.01). Plasma half-life of frusemide varied 7-fold, between 0.60 and 4.27h, and was prolonged substantially in some patients compared with values in normal subjects. There was a highly significant correlation between the apparent volume of distribution and plasma half-life of frusemide (r = 0.938, p < 0.001). Frusemide was eliminated via both renal and non-renal mechanisms in all but 2 patients, who had advanced cirrhosis and eliminated the drug almost exclusively though the kidneys. The apparent volume of distribution was increased proportionally more than the decrease in protein binding explaining in part why higher doses of frusemide are needed in patients with liver disease to obtain the same response as in healthy subjects.

Aged↗